<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">32312500</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>06</Day></DateCompleted><DateRevised><Year>2021</Year><Month>08</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0035-3787</ISSN><JournalIssue CitedMedium="Internet"><Volume>176</Volume><Issue>7-8</Issue><PubDate><Year>2020</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Revue neurologique</Title><ISOAbbreviation>Rev Neurol (Paris)</ISOAbbreviation></Journal><ArticleTitle>Genetic forms of frontotemporal lobar degeneration: Current diagnostic approach and new directions in therapeutic strategies.</ArticleTitle><Pagination><StartPage>571</StartPage><EndPage>581</EndPage><MedlinePgn>571-581</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neurol.2020.02.008</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0035-3787(20)30510-5</ELocationID><Abstract><AbstractText>Recent advances in the genetics of neurodegenerative diseases have substantially improved our knowledge about the genetic causes of frontotemporal lobar degeneration (FTLD). Three major genes, namely progranulin (GRN), C9orf72 and MAPT, as well as several less common genes, are responsible for the majority of familial cases and for a significant proportion of sporadic forms, including FTLD with or without associated amyotrophic lateral sclerosis and some rarer clinical presentations. Plasma progranulin dosage and next-generation sequencing are currently available tools which allow the detection of a genetic cause in a more rapid and efficient way. This has important consequences for clinical practice and genetic counseling for patients and families. The ongoing investigations on some therapeutic candidates targeting different biological pathways involved in the most frequent genetic forms of FTLD, as well as a better understanding of the early pathophysiological modifications occurring during the presymptomatic phase of the disease could hopefully contribute to develop effective disease-modifying therapies. The identification of a causal mutation in a family is of outmost importance indeed to propose to presymptomatic carriers their inclusion in clinical trials with the aim to prevent or delay the onset of disease.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 Elsevier Masson SAS. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sellami</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Inserm U1127, CNRS UMR 7225, Institut du cerveau et de la moelle &#xe9;pini&#xe8;re (ICM), Sorbonne universit&#xe9;, h&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, AP-HP, Paris, France; D&#xe9;partement de neurologie, centre de r&#xe9;f&#xe9;rence des d&#xe9;mences rares ou pr&#xe9;coces, IM2A, h&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, AP-HP, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saracino</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Inserm U1127, CNRS UMR 7225, Institut du cerveau et de la moelle &#xe9;pini&#xe8;re (ICM), Sorbonne universit&#xe9;, h&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, AP-HP, Paris, France; D&#xe9;partement de neurologie, centre de r&#xe9;f&#xe9;rence des d&#xe9;mences rares ou pr&#xe9;coces, IM2A, h&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, AP-HP, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le Ber</LastName><ForeName>I</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Inserm U1127, CNRS UMR 7225, Institut du cerveau et de la moelle &#xe9;pini&#xe8;re (ICM), Sorbonne universit&#xe9;, h&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, AP-HP, Paris, France; D&#xe9;partement de neurologie, centre de r&#xe9;f&#xe9;rence des d&#xe9;mences rares ou pr&#xe9;coces, IM2A, h&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, AP-HP, Paris, France; Institut du cerveau et de la moelle &#xe9;pini&#xe8;re (ICM), FrontLab, h&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, AP-HP, 47-83, boulevard de l'H&#xf4;pital, CS21414, 75646 Paris cedex, France. Electronic address: isabelle.leber@upmc.fr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Rev Neurol (Paris)</MedlineTA><NlmUniqueID>2984779R</NlmUniqueID><ISSNLinking>0035-3787</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036341">Intercellular Signaling Peptides and Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077153">Progranulins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057174" MajorTopicYN="Y">Frontotemporal Lobar Degeneration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036341" MajorTopicYN="N">Intercellular Signaling Peptides and Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077153" MajorTopicYN="N">Progranulins</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">C9orf72</Keyword><Keyword MajorTopicYN="N">Clinical trial.</Keyword><Keyword MajorTopicYN="N">Frontotemporal dementia</Keyword><Keyword MajorTopicYN="N">Frontotemporal lobar degeneration</Keyword><Keyword MajorTopicYN="N">Next-generation sequencing</Keyword><Keyword MajorTopicYN="N">Progranulin (GRN)</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>1</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>2</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>2</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32312500</ArticleId><ArticleId IdType="doi">10.1016/j.neurol.2020.02.008</ArticleId><ArticleId IdType="pii">S0035-3787(20)30510-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>